Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK: LF elimination programme treats 500 million people

GSK: LF elimination programme treats 500 million people

10th October 2008

GlaxoSmithKline (GSK) has announced the publication of a new study showing international work to eliminate lymphatic filariasis (LF) has resulted in over 500 million people receiving treatment.

It added 6.6 million children have also been prevented form acquiring the condition, while 9.5 million people already with LF have been stopped from progressing to more debilitating stages.

The paper was published in the PloS Neglected Tropical Diseases open-access journal and assessed the impact of the World Health Organization sponsored Global Programme to Eliminate LF.

GSK said the positive outcomes are the result of the most rapid scale-up of a drug administration programme in the history of public health.

Dr Mwele Malecela, director of the Tanzania Lymphatic Filariasis Programme and chair of the Global Alliance to Eliminate LF, said: “These data illustrate that with the right partnerships, it is possible to make an extraordinary impact on the health of hundreds of millions of people at minimal cost.”

He added the alliance is on-track to achieve its goal of eliminating the condition by 2020, marking the initiative out as a leading case study on how to scale-up disease elimination programmes.

In May 2006, GSK won the International Chamber of Commerce’s 2006 World Business Award in recognition for its involvement in attempt to eradicate LF.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.